Artificial Heart
Artificial Heart
According to the American Heart Association, an estimated 550,000 new cases of heart failure are diagnosed each year.
An artificial heart is a device designed to completely replace a seriously damaged heart, temporarily take over the function of a failing heart until a donor heart is available for heart transplant, or perform the job of a natural heart during surgery. The two major types of artificial heart are the heart-lung machine and the mechanical heart. The heart-lung machine consists of a pump, which performs the heart's job of pumping blood, and an oxygenator, which performs the lungs' job of supplying oxygen to the blood. This machine is mainly used by surgeons to stop and restart the heart during heart surgery.
A mechanical heart, on the other hand, may be a self-contained artificial heart or a left ventricular assist device (LVAD). The self-contained artificial heart is designed for patients who cannot be helped by any other means and are not eligible for heart transplant. It is also called a total artificial heart because it contains its own power source. The LVAD, on the other hand, is designed to work alongside the heart, taking on the workload of the left ventricle while the patient awaits a heart transplant. The left ventricle, responsible for the pumping action of the heart, is the hardest working of the four chambers (sections) of the heart. It performs about 80 percent of the heart's work and, as such, is usually the part that is weakened by disease.
A tireless worker
The heart is a hard-working organ that continually moves blood throughout the whole body. It has four chambers. The upper chambers, or the atria (singular: atrium), receive the blood that flows back to the heart through the veins. The lower chambers, or the ventricles, pump the blood out of the heart through the arteries.
Blood enters the right atrium through the veins and fills the right atrium. The right atrium pumps the blood through a valve into the right ventricle, which in turn pumps the blood to the lungs through another valve. The person breathes out carbon dioxide and breathes in oxygen. The oxygen-rich blood goes back to the heart, entering through the left atrium. The left atrium sends the blood into the left ventricle, which pumps it out to the body through the aorta, the largest artery of the body. Smaller blood vessels branching out of the aorta carry the blood to different parts of the body.
Heart failure
Congestive heart failure is the steadily declining ability of the heart to pump blood. It is one of the leading causes of death. Some people are born with a defective heart or may have caught a virus that damaged the heart. In others, the disease may be caused by high blood pressure, sudden damage from a heart attack, or other medical problems. Still others have developed the disease as a result of smoking, eating foods high in fat and cholesterol, not exercising, or being overweight. According to the American Heart Association, almost five million Americans suffer from heart failure, and an estimated 550,000 new cases are diagnosed each year. Although it usually affects older people, heart failure is also seen in children and young people.
FAMOUS FIRSTS
In 1967, South African doctor Christiaan Barnard (1922–2001) performed the world's first human heart transplant. Barnard replaced the failing heart of Louis Washkansky with that of a young woman killed in a car accident. Washkansky survived for eighteen days.
On December 18, 1985, 41-year-old Mary Lund became the first woman to receive an artificial heart. The Jarvik-7, which had been designed for adult males, had to be modified in size to fit her. The artificial heart supported Lund's natural heart while she waited for a heart transplant.
First artificial hearts
Since the late 1800s, medical researchers have tried to develop a mechanical device to temporarily take over the heart's function of pumping blood. In 1935, American surgeon John H. Gibbon (1903–73) invented the first heart-lung machine. It took him nearly twenty years to perfect his invention. In 1953, Gibbon used the machine to perform the first open-heart surgery on an 18-year-old patient. Four years later, Dr. Willem Kolff (1911–), a Dutch-born physician, implanted the first artificial heart into a dog.
While Kolff was working on building a total artificial heart, other researchers were developing artificial devices for patients who were waiting for a heart transplant or for those whose hearts were not functioning fully. In 1963, Dr. Michael DeBakey (1908–) implanted a pump with internal valves in a patient. The plastic banana-shaped device helped move the blood through the chambers of the heart. In 1966, Dr. Adrian Kantrowitz (1918–) implanted a partial mechanical heart in a human. That same year, DeBakey implanted the first LVAD.
Denton Cooley (1920–) and his surgical team at the Texas Heart Institute (Houston, Texas) performed the first temporary human artificial heart implant in 1969, using a device designed by Argentine-born Domingo Liotta (1924–). The artificial heart was a double-ventricle pump, made of plastic and synthetic polyester fabric. It was air-driven by an external console, a cabinet-like structure about the size of a home washing machine with a control panel. The artificial heart kept Haskell Karp alive for almost three days, after which time he had a heart transplant.
A complete replacement heart
The first time that an artificial heart totally replaced a diseased human heart occurred on December 2, 1982. Dr. William DeVries (1943–) implanted the Jarvik-7 heart into Barney Clark (1921–1983). Clark was too sick to qualify for a donor heart, so the device would be a permanent heart for the 61-year-old patient. Named after its inventor, Dr. Robert Jarvik (1946–), the artificial heart was slightly bigger than the human heart and weighed about the same (10 ounces, or 280 grams). The device was made of plastic on an aluminum base and consisted of two pumping ventricles (lower heart chambers) connected to the upper chambers of the patient's heart. The pumping action came from compressed air delivered by an electrical console outside the patient's body. Two air hoses, inserted through abdominal incisions (cuts), were connected to the artificial ventricles. Clark survived for 112 days before finally dying from infection and blood vessel blockage resulting from blood clots.
DeVries performed four other implants using the Jarvik-7. The patients eventually died, including William Schroeder (1932–1986), who lived for 620 days. Further ventures in inventing a permanent artificial heart came to a halt, especially because of the problems encountered in its use—the formation of blood clots that traveled to the brain, causing strokes; the occurrence of infection due to the abdominal incisions and the opening of the patient's chest during surgery; and the patient's inability to move around because of the bulky console that was about the size of a home refrigerator.
Redesigning the artificial heart
In the 1990s, medical researchers turned their attention to designing mechanical devices to help weakened hearts function until a donor heart was available. In 1994, the U.S. Food and Drug Administration (FDA), the government agency responsible for approving medical devices, approved such a device. The HeartMate® Implantable Pneumatic Left Ventricular Assist System (IP LVAS) was a titanium alloy pump implanted in the abdominal area and connected to the left ventricle. From the left ventricle, the device pumped the blood into the aorta, supplying the whole body with blood. The device was powered by an external console on a movable cart, which ran on electricity or battery (for thirty minutes).
In 1998, the FDA approved portable versions of the LVAD that are powered by a small external battery-run computerized controller worn at the waist or under the arm. The two rechargeable batteries have to be charged every six to eight hours. The devices usually have backup batteries and a hand pump that the patient can operate.
Design
Several important issues must be addressed when designing a LVAD. The designer has to make sure that enough blood is pumped. The external console must have a fixed mode as well as an automatic mode so that the pump can be adjusted to adapt to the patient's needs. The fixed mode ensures that the pump rate is the same all the time, while the automatic mode enables the system to make adjustments to the blood flow depending on what the patient requires.
The designer must also make sure that no blood clots are created. Materials must be biocompatible, which means that they must be able to coexist with the body tissue and not be rejected by it. Otherwise, the pump could fail. For the same reason, the total weight and size are important considerations. Some LVADs weigh as little as 1.25 pounds (570 grams) and measure about 2 inches (5 centimeters) thick and 4 inches (10 centimeters) in diameter. In addition, the motor must run at its most efficient level so that minimal heat is generated.
A LVAD pump generally consists of a blood chamber, an air chamber, inflow and outflow tubes, and a driveline for connecting to the external power source. The inflow tube attached to the left ventricle moves the blood to the blood chamber. An external control starts the pumping action. A pusher plate "pushes" the flexible diaphragm (separating membrane between the two chambers) upward, thus pressurizing the air chamber. This action ejects the blood through the outflow tube attached to the aorta, pumping the blood to all parts of the body.
Raw Materials
Since the left ventricle is the hardest-working of the four chambers of the heart, it is the most likely to get weak. The completely implantable artificial heart (the AbioCor™; see The Future) is still undergoing human testing; therefore, LVADs, currently the most widely used of the artificial hearts, will be discussed here. As of 2002, over 4,000 LVADs had been implanted in patients worldwide waiting for a heart transplant.
The LVAD is made of metal, plastic, ceramic, and animal parts. A titanium-aluminum-vanadium alloy is used for the pump and for other metal parts because it not rejected by the patient's body. The titanium parts are shaped at a specialized titanium processor and, except for surfaces that will have contact with blood, the titanium is given a certain finish. Blood-contacting surfaces are bonded with special titanium microspheres, which are tiny beads of titanium that produce textured surfaces.
A diaphragm within the pump is made from plastic polyurethane that is also textured. The textured surfaces of the titanium and the diaphragm are very important. When blood comes in contact with the textured surfaces, it deposits circulating blood cells, which stick to the surfaces, creating a living lining inside the device that resembles the inner surfaces of veins (blood vessels that return blood to the heart) and arteries (blood vessels that carry blood away from the heart). This helps prevent the formation of blood clots inside the LVAD.
The two tubular grafts that are used to attach the LVAD to the aorta and the left ventricle are made from polyester. The valves used are actual heart valves from a pig. The motor is made from titanium or other metals and ceramics.
The Manufacturing Process
Most components of the LVAD are made according to specifications by third-party manufacturers, including machine shops and manufacturers of the printed circuit board. A medical-device firm that specializes in heart valves sews the valves inside the tubular grafts with sutures.
Forming the plastic polyurethane parts
1 Some LVAD manufacturers make their own plastic polyurethane parts. One process uses a plastic liquid solution that is made by the manufacturer. This solution is poured on a ceramic mold layer by layer. Each layer is heated and dried until the desired thickness is achieved. The part is then removed from the mold and inspected. The polyurethane parts may be made by an outside manufacturer using injection molding, in which melted plastic is forced into a mold under high pressure and then allowed to cool. As it cools, the plastic assumes the shape of the mold.
Assembly
2 Each LVAD takes several days to assemble and test. The assembly takes place in a clean room to avoid contamination. Each LVAD consists of up to fifty components that are put together with special adhesives that have been strengthened at high temperatures.
3 Several assembly operations are done at the same time, including the assembly of the motor housing and components, the attachment of the pusher plate to the polyurethane diaphragm, and the assembly of the percutaneous tube. The percutaneous (administered through the skin) tube, as its name implies, is a small tube containing control and power wires that pass through the patient's skin and connect the LVAD to the power source. These subassemblies are individually inspected. The complete system is then put together. The tubular grafts are assembled separately and attached during surgery.
Testing
4 After the components are put together, each device is tested, using special equipment that mimics conditions the device would encounter once implanted in the body. All electronic parts are also tested to ensure the proper functioning of all electric circuitry.
Sterilization and packaging
5 After the LVAD has passed the testing, it is sent to an outside service for sterilization to destroy germs that may cause infection. Each device is sealed in plastic trays and returned to the heart manufacturer. It is then packaged in specially made suitcases to protect it from contamination and to prevent damage.
The Future
Heart disease remains the number one cause of death in the United States. As baby boomers (people born between 1946 and 1964) age, the number of people in need of healthy hearts will increase dramatically. Each year, an estimated 45,000 Americans need a heart transplant; however fewer than 3,000 donor hearts are available. Faced with this problem, scientists continue to develop artificial hearts as potential alternatives.
On July 2, 2001, the first-ever completely self-contained artificial heart (with power supply included) was implanted in a human. Drs. Laman Gray and Robert Dowling of the University of Louisville, Kentucky, removed Robert Tools's damaged heart, while leaving major blood vessels on which to attach the AbioCor™ Implantable Replacement Heart. Jointly developed by the Texas Heart Institute and Abiomed, Inc., the device is about the size of a softball and weighs 2 pounds (907 grams). Robert Tools died on November 30, 2001, from complications, which, according to his doctors, were unrelated to his artificial heart. Tom Christerson became the world's second recipient of the AbioCor™ Implantable Replacement Heart on September 13, 2001. Prior to his artificial-heart surgery, Christerson was not expected to live more than a month. On April 16, 2002, he was able to go home to his family. As of June 18, 2002, Drs. Gray and Dowling announced that the patient was doing well.
The AbioCor™ heart is powered by an external battery that passes electricity through the patient's skin (without any skin piercing) to a power receptor in the chest. An electronic monitor is implanted in the abdominal area to regulate the pumping speed. An internal battery continually charged by the external batteries serves as an emergency power source, as well as allows the patient to perform certain activities, such as take a shower, without the batteries. In January 2002, the manufacturer of AbioCor™ announced that it had removed a plastic cage in the design that may have caused blood clotting and led to stroke in at least one patient. The AbioCor™ heart will likely undergo different stages of testing before it can be commercially sold. In the meantime, Abiomed, Inc. is working on a smaller version of the AbioCor™ heart.
Pennsylvania State University researchers had also been developing a complete artificial heart. In September 2000, Abiomed, Inc., acquired the rights to the Penn State Heart. Abiomed and Penn State's College of Medicine will work together to continue developing the device.
Several heart-assist devices are also undergoing various stages of testing. The Kantrowitz CardioVad™, developed by Dr. Adrian Kantrowitz, is the only device that allows a patient to turn it on and off. Krantrowitz, the first U.S. surgeon to perform a heart transplant, spent thirty years fine-tuning the device. It is designed for patients with chronic (recurring) congestive heart failure who are not qualified for a heart transplant. It has three main parts—a pumping bladder weighing less than 1 ounce (about 28 grams), a couple of tubes leading from the pumping bladder (one for sending information to an attached computer and the other for inflating and deflating the bladder), and an external power source. The patient receives two power sources, a 5-pound, (2.3-kilogram) battery-powered unit and a unit the size of a small suitcase on wheels. Unlike other open-heart surgeries to implant heart devices, in which the breastbone is split open, the procedure to insert the CardioVad™ involves going through two ribs on the left chest. The device is sewn into the aorta, and a wire is run through the abdomen for linkage to the power source.
IMPROVING THE QUALITY OF LIFE
Researchers supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health found, in a three-year study of patients with severe heart failure, that the use of a left ventricular assist device (LVAD) had helped extend the patients' lives. In addition, the medical device also improved their emotional state and physical function. These patients had been terminally ill and were ineligible for heart transplant due to their age or certain medical conditions.
Smaller types of LVADs are also being tested. The Jarvik-2000 Flow-maker, invented by Dr. Robert Jarvik, the inventor of the first replacement heart, Jarvik-7, is about the size of a C battery. The small titanium turbine pump fits into the left ventricle and is powered by an external battery.
Another small-sized LVAD has been invented by Dr. Michael DeBakey, Dr. George Noon (1934–), and NASA (National Aeronautics and Space Administration) engineers. Borrowing from space technology, the MicroMed DeBakey Ventricular Assist Device™ uses very light materials and computer chips. It weighs less than 4 ounces (113 grams) and has a simple moving part called the inducer-impeller. The titanium device, about the size of a walnut, plugs into the left ventricle and is powered by an external battery, connected by an inner-ear implant attached to the skull.
- alloy:
- A mixture of a metal and a nonmetal or a mixture of two or more metals.
- aorta:
- The main artery that carries blood away from the heart to the different parts of the body.
- artery:
- A blood vessel that carries blood away from the heart.
- atrium:
- One of the two upper chambers of the heart that receives blood from the veins and pumps it to the ventricles.
- blood clot:
- A solid mass of blood that can block the movement of blood.
- chamber:
- One of the four sections of the heart through which blood is pumped.
- donor heart:
- A healthy heart obtained from a person who has just died and used for such purposes as a heart transplant. Persons who have voluntarily given permission for their organs to be used after their death typically carry a donor card, stating their intent.
- heart transplant:
- Also called heart transplantation; the process of replacing a diseased heart with a healthy heart from a person who has just died.
- stroke:
- A sudden blockage or bursting of a blood vessel in the brain, interrupting the blood flow to part of the brain.
- valve:
- In living hearts, one of the four flaps of tissue between the chambers that prevents the backward flow of blood. In artificial hearts, the flap-like structure that allows blood to flow in one direction.
- vein:
- A blood vessel that returns blood to the heart.
- ventricle:
- Either of the two lower chambers of the heart, which receives blood from the atria, or upper chambers, and pumps it into the arteries.
For More Information
Books
Berger, Melvin. The Artificial Heart. New York, NY: Franklin Watts, 1987.
Yount, Lisa. "From Sausage Casings to Six-Million-Dollar People." In MedicalTechnology. New York, NY: Facts On File, Inc., 1998.
Periodicals
Rose, Eric A. et al. "Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure." The New England Journal of Medicine (November 15, 2001): pp. 1435–1443.
Westaby, Stephen et al. "First Permanent implant of the Jarvik 2000 Heart." TheLancet (September 9, 2000): pp. 900–905.
Web Sites
"Affairs of the Heart." Public Broadcasting System.http://www.pbs.org/saf/1104/features/substitute.htm (accessed on July 22, 2002).
"The Heart: An Online Exploration." The Franklin Institute Online.http://sln.fi.edu/biosci/heart.html (accessed on July 22, 2002).
"Heartmate® Implantable Pneumatic Left Ventricular Assist System." Texas HeartInstitute.http://www.bcm.tmc.edu/tmc/thi/iplvas.html (accessed on July 22, 2002).
More From encyclopedia.com
NEARBY TERMS
Artificial Heart
